A few months ago we highlighted
work out of AstraZeneca detailing how to build a covalent fragment library. One
of the design features was including larger molecules beyond the traditional
rule of three (Ro3) criteria. A new open-access paper in J. Med. Chem. by
György Keserű and collaborators at the HUN-REN- Research Centre for Natural
Sciences and the Weizmann Institute of Science explores “size-dependent target
engagement of covalent probes.”
The paper starts with a theoretical
discussion of covalent inhibitors, focusing on the classic two-step mechanism
in which binding of a ligand to a protein is followed by covalent bond
formation. These steps are characterized by the inhibition constant (KI)
and the inactivation rate constant (kinact). The most
appropriate way to assess an irreversible covalent inhibitor is by the ratio kinact/KI,
as we discussed last year.
A two-step mechanism is not the
only possibility: the researchers also consider a three-step model in which binding
of the ligand is followed by a second step, deprotonation of the amino acid
nucleophile, before the final bond-forming step.
Fragments typically have lower
affinities than lead-size or drug-size molecules, and thus kinact
will usually need to be higher for smaller molecules in order to see significant
protein labeling. Simulations in which KI is held constant show that at the high micromolar affinities often seen for fragments, protein modification requires either long incubation times or high reactivities. In addition to these simulations, the researchers also reanalyze publications
we’ve previously covered such as this and this to argue that “reactivity
contributes to labeling when the effects of other factors cancel out.”
Next, the researchers examine the
kinase BTK and the oncology target KRAS, both of which have been successfully
drugged with covalent molecules, ibrutinib and adagrasib, respectively. They
trimmed back these molecules to smaller lead-like and fragment-like molecules
and found that while some lead-sized molecules could still label the proteins,
this was not the case for the fragment-sized molecules. From this they conclude
that “fragment-sized covalent agents do not offer smooth optimization and are
not ideal starting points.”
Two examples do not a trend make,
but the researchers point to other examples in the literature. In 2020 we noted
the larger size of covalent KRAS hits, and Vividion’s WRN inhibitor also
started from a molecule with a molecular weight of 337 Da, while GSK’s starting point weighs in at 312 Da. The AstraZeneca library we mentioned at the start of
this post yielded a hit against BFL1 that also just missed the Ro3 cutoff, coming
in at 302 Da.
That said, there are counterexamples.
Just last month we highlighted a covalent fragment hit that fits comfortably
within the rule of three. Fragment-sized covalent hits can be found, but don’t
expect them to be common. The alternative approach, screening lead-like
compounds, will also likely require screening more compounds due to lower coverage
of chemical space. Either way, libraries containing more molecules are likely to
be beneficial for finding covalent starting points.